How close are we to a cAMP- and cGMP-theory-based pharmacological therapy for fragile X syndrome?
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 39970871.
- Also identified by DOI 10.1016/j.xcrm.2025.101972 and PMC identifier 11866550.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Recent advances in targeting cAMP and cGMP pathways offer hope for treating fragile X syndrome, a leading cause of inherited intellectual disability. PDE4 and PDE2 inhibitors have shown promise in animal models, improving memory, social behavior, and cognitive function. Clinical trials are underway, raising optimism for future therapies.
Medical subject headings
- Cyclic AMP
- Cyclic GMP
- Fragile X Syndrome